Nuvation Bio Inc
NUVB_t0.228USD
+0.001+0.48%
Close 08/01, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Nuvation Bio Inc Company
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Company Info
Ticker SymbolNUVB_t
Company nameNuvation Bio Inc
IPO dateJul 01, 2020
CEODr. David T. Hung, M.D.
Number of employees- -
Security type- -
Fiscal year-end- -
Address357 Tehama Street, Floor 3
CitySAN FRANCISCO
Stock exchange- -
CountryUnited States of America
Postal code94103
Phone14157543517
Websitehttps://www.nuvationbio.com/
Ticker SymbolNUVB_t
IPO dateJul 01, 2020
CEODr. David T. Hung, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. Joe Rayne
Mr. Joe Rayne
Investor Relations
Investor Relations
--
--
Mr. Philippe Sauvage
Mr. Philippe Sauvage
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
--
--
Ms. Stacy Markel
Ms. Stacy Markel
Chief People Officer
Chief People Officer
--
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Gary Hattersley, Ph.D.
Dr. Gary Hattersley, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
--
--
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
--
--
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
--
--
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. Joe Rayne
Mr. Joe Rayne
Investor Relations
Investor Relations
--
--
Mr. Philippe Sauvage
Mr. Philippe Sauvage
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
--
--
Ms. Stacy Markel
Ms. Stacy Markel
Chief People Officer
Chief People Officer
--
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Gary Hattersley, Ph.D.
Dr. Gary Hattersley, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Feb 28
Updated: Fri, Feb 28
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
30
31.74M
0.00%
+26.49M
2025Q1
30
31.74M
0.00%
+26.49M
2024Q4
31
4.90M
0.00%
-302.14K
2024Q3
30
4.86M
0.00%
-182.30K
2024Q2
31
4.71M
0.00%
+261.45K
2024Q1
29
4.01M
0.00%
-276.84K
2023Q4
27
4.00M
0.00%
-301.37K
2023Q3
26
4.18M
0.00%
-276.64K
2023Q2
26
4.34M
0.00%
-268.70K
2023Q1
26
4.49M
0.00%
-128.42K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rock Springs Capital Management LP
134.03K
0%
--
--
Mar 31, 2025
Samsara BioCapital, LLC
133.33K
0%
--
--
Mar 31, 2025
Greenlight Capital, Inc.
100.00K
0%
--
--
Mar 31, 2025
Acuta Capital Partners, LLC
90.83K
0%
--
--
Mar 31, 2025
Citadel Advisors LLC
73.55K
0%
-408.00
-0.55%
Mar 31, 2025
Logos Global Management LP
66.67K
0%
--
--
Mar 31, 2025
Victory Capital Management Inc.
58.11K
0%
-440.00
-0.75%
Mar 31, 2025
Intellectus Partners, LLC
22.40K
0%
--
--
Mar 31, 2025
Boxer Capital Management, LLC
266.67K
0%
--
--
Mar 31, 2025
EcoR1 Capital, LLC
963.33K
0%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
